多瑞醫藥(301075.SZ):擬斥不超2500萬元參與海融醫藥定增 佔股0.98%
格隆匯6月29日丨多瑞醫藥(301075.SZ)公佈,為促進公司完善整體產業佈局,提升核心競爭力,與國內優秀醫藥研發企業建立緊密的合作與交流,公司擬按照47.46元/股的價格,以現金方式認購南京海融醫藥科技股份有限公司(簡稱“海融醫藥”)定向發行的股票52.6759萬股,預計投資總額不超過約2500萬元人民幣。
公司擬與海融醫藥(870070.OC)簽訂《南京海融醫藥科技股份有限公司與西藏多瑞醫藥股份有限公司之定向發行認購協議書》。該次交易完成後,海融醫藥發行總股本由5267.0869萬股擬增加至5395.5628萬股,公司將持有海融醫藥股份佔發行後總股本的0.98%(具體以海融醫藥股票發行實際認購結果為準)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.